Abstract:
As of 8 January 2021, there were 86,749,940 confirmed coronavirus disease 2019 (COVID19) cases and 1,890,342 COVID-19-related deaths worldwide, as reported by the World Health
Organization (WHO). In order to address the COVID-19 pandemic by limiting transmission, an
intense global effort is underway to develop a vaccine against SARS-CoV-2. The development of a
safe and effective vaccine usually requires several years of pre-clinical and clinical stages of evaluation
and requires strict regulatory approvals before it can be manufactured in bulk and distributed. Since
the global impact of COVID-19 is unprecedented in the modern era, the development and testing of
a new vaccine are being expedited. Given the high-level of attrition during vaccine development,
simultaneous testing of multiple candidates increases the probability of finding one that is effective.
Over 200 vaccines are currently in development, with over 60 candidate vaccines being tested in
clinical trials. These make use of various platforms and are at different stages of development. This
review discusses the different phases of vaccine development and the various platforms in use for
candidate COVID-19 vaccines, including their progress to date. The potential challenges once a
vaccine becomes available are also addressed.
